TerrAscend Corp is a Golden State warrior, says Clarus Securities

Cannabis company TerrAscend Corp (TerrAscend Corp Stock Quote, Chart CSE:TER) is getting a target price raise from Clarus Securities on the recent acquisition of the California operations of the Apothecarium.

In a June 12 update to clients, analyst Noel Atkinson maintained his “Buy” rating with the new target of C$12.75 (was C$12.50).

Last week, TerrAscend announced the closing of its $36.8-million purchase of the Apothecarium’s California operations, with the acquisition of its Nevada operations expected sometime in the third quarter of this year. (All figures in US dollars unless noted otherwise.)

The California purchase includes three dispensary locations in San Francisco, a Berkeley location which is zoned and under construction, an undisclosed fifth location somewhere in the Bay Area as well as Valhalla Confections, an edibles company.

Atkinson says that while California’s cannabis sector remains highly fragmented, with 631 active licenses for cannabis dispensaries, the pipeline for expansion in the state remains robust.

“We believe the California cannabis sector is not overbuilt. There are about 63,000 Californians per licensed dispensary, versus about 25,000 people per dispensary in Nevada, 15,000 in Washington, 7,500 in Colorado and less than 7,000 people per dispensary in Oregon (the other large mature adult-use states),” says Atkinson.

Atkinson says closing the California deal with the Apothecarium makes TerrAscend one of the largest retail dispensary operators in the Golden State and that the sooner-than-expected closing of the deal is cause for a raise in his estimates.

The analyst thinks TerrAscend will generate fiscal 2019 revenue and adjusted EBITDA of $142.5 million and $4.5 million (previously $136.3 million and $1.0 million) and fiscal 2020 revenue and adjusted EBITDA of $372.2 million and $96.5 million (was $365.5 million and $91.9 million).

Atkinson’s C$12.75 target represented a projected return of 90.3 per cent at the time of publication.

More Cantech Cannabis

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ter
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

2 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

2 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

2 days ago

Rogers is an undervalued stock, RBC says

With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]

3 days ago

Tornado Global Hydrovacs is still a double, Beacon says

Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]

3 days ago

Sell your Molson Coors stock, Citi says

Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]

4 days ago